What is Inocras?
Founded in 2020 by a multidisciplinary team of physician-scientists, geneticists, and bioinformaticians, Inocras operates at the intersection of clinical diagnostics and data science. The company has developed an IP-protected technology stack that enables the extraction of actionable insights from complex genomic data. By maintaining a CLIA-certified and CAP-accredited laboratory, Inocras ensures the highest standards of operational excellence, bridging the gap between raw genetic information and personalized therapeutic interventions. Its market position is defined by its ability to integrate multi-omics data with proprietary AI-driven analysis, providing a robust framework for modern healthcare providers to improve patient outcomes.
How much funding has Inocras raised?
Inocras has raised a total of $36.7M across 2 funding rounds:
Series A
$5.7M
Series B
$31M
Series A (2020): $5.7M, investors not publicly disclosed
Series B (2026): $31M led by Korea Investment & Securities, NDS, Dunamu & Partners, DSC Investment, Woori Investment Bank, InterVest Capital Partners, AimedBio, Dt&Investment, IMM Investments, and Shinhan Securities Silicon Valley
Key Investors in Inocras
Korea Investment & Securities
A leading Korean financial institution specializing in asset management, investment banking, and securities brokerage with a strong track record in facilitating major IPOs and capital market development.
Dunamu & Partners
The investment arm of Dunamu, focusing on high-growth startups within the blockchain, fintech, and AI sectors to foster societal innovation.
IMM Investments
A prominent Asian multi-asset alternative investment firm providing multi-stage capital, ranging from early-stage venture to large-scale growth equity and infrastructure projects.
What's next for Inocras?
The infusion of capital from this latest financing round will be instrumental in scaling Inocras's operational infrastructure and expanding its diagnostic capabilities. As the company transitions from its initial development phase into a period of rapid commercial scaling, the focus will likely shift toward broadening its clinical partnerships and enhancing its proprietary platform's predictive accuracy. By leveraging its recent backing, Inocras is poised to solidify its footprint in the global precision medicine market, potentially exploring new therapeutic areas and deepening its integration within the clinical research ecosystem. The strategic alignment with its current investor base provides the necessary resources to navigate the complexities of the biotech landscape while maintaining its commitment to scientific rigor and diagnostic innovation.
See full Inocras company page
